Responding to the rapidly changing domestic and international environment, Semmelweis University has established a number of university-owned companies in recent years. With the help of these companies, the University now offers a variety of business services and aims to strengthen its position as an attractive partner for those seeking investment and cooperation opportunities in Hungary.
Click on the links below for a brief overview of each company.
Wholly owned by the University, Semmelweis Health Care Service Ltd. (SEK) offers high quality private health care services using Semmelweis University’s clinical background and the expertise and professional experience of its clinical physicians. Its services are sought out by Hungarian and international patients alike, for a variety of reasons, including long waiting lists, the particular service not being covered by the National Health Service Fund (OEP), or simply because they wish to receive superior care.
The services are provided by the University’s current and former specialist doctors at the University’s various clinical departments in offices specially designed for the purpose.
Semmelweis University has a 100% ownership over Semmelweis Publishing and Multimedia Studios Ltd. Its express intent is to serve Hungarian medical, pharmaceutical, and natural science with due humility and in a way that is worthy of the University’s national and international reputation, while taking a decidedly new and modern approach.
It strives to be a professional and quality member of the Hungarian specialised publishing industry while maintaining the medical, pharmaceutical and natural science publishing traditions. This is made possible by our experienced and committed staff, working under the direction of an excellent management team.
Website: www.semmelweiskiado.hu (in Hungarian only)
Managing director: dr. László Táncos
Address: 1089 Budapest, Nagyvárad tér 4.
Tel.: (+36 ) 210-4403
Fax: (+36 1) 210-1904
The Bionic Innovation Non-profit Ltd. was founded by Semmelweis University and Pázmány Péter Catholic Universtiy with the aim of establishing the state sponsored Bionic Innovation Centre (BIK), and its foundation stone was laid down in March 2015. One of the priority research areas of the Centre is to develop applications for patient care based on theranostics (theranostics = therapy+diagnostics), which exceeds the quality and cost efficiency of previous methods of patient care. They strive to introduce and develop the so-called “lab-on-a-chip” mobile devices, which would enable laboratory tests to be carried out either with inpatients or outpatients, requiring a minimal amount of samples.
Semmelweis University has a 100% ownership over SMS Ltd, which aims to manage and organise the seamless enrollment of foreign students at Semmelweis University.
With the help of its international network of international the company promotes the university’s foreign language programmes and organises both the application and enrollment procedures.
Managing director: dr. Márk Kollai
Address: 1094 Budapest, Tűzoltó u. 37-47.
Telephone: +36 30 312 46 63
The European Commission’s Research Executive Agency, the National Research, Development and Innovation Office, the Hungarian Academy of Sciences, the Hungarian Academy of Sciences Biological Research Centre in Szeged, the University of Szeged, the University of Debrecen, Semmelweis University and the European Molecular Biology Laboratory (“EMBL”) signed a multilateral agreement within the framework of Horizon 2020 programme. The agreement promotes institutions’ cooperation in the realisation of research and development projects, the identification and achievement of goals, including the foundation of the HCEMM Molecular Medicine Excellence Centre.
HCEMM Ltd. was founded by Semmelweis University, the University of Szeged, and the Hungarian Academy of Sciences Biological Research Centre in Szeged.
HCEMM Ltd. (HCEMM) is a new excellence centre with headquarters in Szeged, which will provide research- and educational services in the field of molecular medicine.